Please wait a minute...
93TMR Cancer  2019, Vol. 2 Issue (3): 212-215    DOI: 10.12032/TMRC201800053
Clinical Cancer Research     
Combination of Chinese and Western medicine in the treatment of aggressive angiomyxoma: a case report
Yan Liu1, Zheng-Wei Jiao2, Teng Huang1,Si-Ning  Ha2,Yan-Bo  Zuo1, Xiao-Shi Jin2,*()
1. Department of Medicine, Hebei University, Baoding, Hebei 071000, China
2.Affiliated Hospital of Hebei University, Baoding, Hebei 071000, China.
Download: HTML     PDF(372KB)
Export: BibTeX | EndNote (RIS)      


Although aggressive angiomyxoma (AAM) has some characteristics of malignant tumors, it does not cause distant metastasis.

Surgery combined with traditional Chinese medicine treatment may be a new way to treat AAM.


Aggressive angiomyxoma(AAM) is a tumor that occurs mainly in women, and its mechanism and treatment are still in the exploratory stage. Traditional Chinese medicine may exert a certain effect in the treatment of AAM. But the mechanism that works is still in need of further laboratory research.


Aggressive angiomyxoma (AAM) is a rare soft tissue tumor. Invasiveness and recurrence are important clinical features of AAM. A patient with recurrent AAM was admitted to the hospital.At present, the treatment for AAM is still based on surgerybecause it does not have lymph nodes and distant metastasis. Moreover, chemotherapy is of little significance. Traditional Chinese medicine believes the formation of tumor is related to blood stasis, so after surgery, a Chinese medicine called Xue-Shuan-Tong was used to improve blood circulation and disperses stasis. The drainage tube was removed on the 5th day after the operation and achieved a good wound healing. This article analyzes and demonstrates the pathogenesis of female vulvar invasive angiomyxoma from the perspective of modern medicine and traditional medicine, in order to provide a better understanding of the disease.

Key wordsAggressiveangiomyxoma      Modern medicine      Traditional Chinese medicine     
Received: 19 May 2019      Published: 02 September 2019
Corresponding Authors: Jin Xiao-Shi   
Cite this article:

Yan Liu , Zheng-Wei Jiao, Teng Huang , Si-Ning Ha , Yan-Bo Zuo , Xiao-Shi Jin . Combination of Chinese and Western medicine in the treatment of aggressive angiomyxoma: a case report. 93TMR Cancer, 2019, 2(3): 212-215. doi: 10.12032/TMRC201800053

URL:     OR

Figure 1 Pelvic CT of the patient A, The FVAAM upward communication with the pelvic cavity; B, The cervix was pressed to the right.
Note: FVAAM, female vulvaraggressiveangiomyxoma.
Figure 2 General appearance of FVAAM.
Note:FVAAM, female vulvaraggressive angiomyxoma.
Figure 3 Microscopic pathology of the tumor The arrows indicate the blood vessels in the FVAAM.
Note: FVAAM, female vulvaraggressiveangiomyxoma.
1.   Guo RJ, Qi Y, Liu S.Clinical analysis and literature review of 12 cases of invasive angiomyxoma. Chin J Practical Gynecol Obstet 2014, 1:55-58.
2.   Steeper TA Rosai J. Aggressive angiomyxoma of the female pelvis and perineum. Report of nine cases of a distinctive type of gynecologic soft-tissue neoplasm. Am J Surg Pathol 1983, 7: 463-475.
3.   McCluggage WG.A review and update of morphologically bland vulvovaginal mesenchymal lesions. Int J Gynecol Pathol 2005, 24: 26-38.
4.   Yan H, Qin XG, Ren Y.Imaging diagnosis of invasive angiomyxoma. Chin J Clin Med Imag 2018, 29: 645-648.
5.   Liang HX, Zhao J.Invasive angiomyxoma with vestibular gland abscess: a case report. China J Modern Med 2011, 21:1067-1068.
6.   Simo M, Zapata C, Esquius J, et al. Aggressive angiomyxoma of the female and perineum: report of two cases and review of the literature. Br J Obstet Gynecol 1992, 99: 925-927.
7.   Elchalal U, Lifschitz-Mercer B, Dgani R, et al. Aggressive angiomyxoma of the vulva. Gynecol Oncol, 1992, 47: 260-262.
8.   Mathieson A, Chandrakanth S.Aggressive angiomyxoma of the pelvis: a case report. Can J Surg 2007, 50: 228-229.
9.   Haldar K, Martinek IE, Kehoe S.Aggressive angiomyxoma: a case series and literature review. Eur J Surg Oncol 2010, 36: 335-339.
10.   Han-Geurts IJ, van Geel AN, van Doorn L, et al. Aggressive angiomyxoma: multimodality treatments can avoid mutilating surgery. Eur J Surg Oncol 2006, 32: 1217-1221.
11.   Sutton BJ, Laudadio J.Aggressive angiomyxoma. Arch Pathol Lab Med 2012, 136: 217-221.
12.   Shinohara N, Nonomura K.Medical management of recurrent aggressive angiomyxoma with gonadotropin-releasing hormone agonist. Inter J Urol 2004, 11: 432-435.
13.   Fine BA, Munoz AK, Litx LE, et al. Primary medical management of recurrent aggressive angiomyxoma of the vulva with a gonadotropin-releasing hormone agonist. Gynecol Oncol 2001, 81: 120-122.
14.   Zhao LM, Ye LH."Synopsis of prescriptions of the golden chamber" and tumor therapy. J Zhejiang Univer Tradit Chin Med 2015, 39:632-635.
[1] Jia Wang, Zhu Yang, Feng-Xi Long, Jin-Lin Wu, Ting Yu, Dong-Xin Tang. The role of Fuzheng Peiben in clinical oncology[J]. 93TMR Cancer, 2019, 2(4): 247-254.
[2] Hui-Li Shui, Zhu Yang , Feng-Xi Long , Wen-Qi Huang , Bing Yang , Zhen Zhang , Dong-Xin Tang. The differences and similarities between regional ethnic medicine and traditional Chinese medicine in the prevention and treatment of cancer pain[J]. 93TMR Cancer, 2019, 2(3): 206-211.
[3] Shi-Yun Shao, Qi Li . Research progress in the treatment of colorectal cancer in classical prescriptions[J]. 93TMR Cancer, 2019, 2(3): 200-205.
[4] Shan-Qi Guo, Xiao-Jiao Gao, Xiao-Jiang Li, Ying-Jie Jia. Traditional Chinese Medicine for Treatment of Apatinib-induced Hand and Foot Skin Reaction:A case report[J]. 93TMR Cancer, 2019, 2(2): 189-192.
[5] Gao Li, Dong-Xin Tang, Feng-Xi Long, Zhu Yang. Advances in research on tumor microenvironment of hepatocellular carcinoma[J]. 93TMR Cancer, 2019, 2(1): 143-150.
[6] Yu-Yu Feng. Significance, feasibility, and perspectives of network pharmacology in treating cancer[J]. 93TMR Cancer, 2018, 1(4): 105-110.
[7] Cui-Ying Miao, Feng-Xi Long, Dong-Xin Tang, Qi-Liang Chen, Guang-Hui Ran. Study of the similarities and differences between TCM and Tujia medicine in clinical diagnosis and treatment of liver cancer[J]. 93TMR Cancer, 2018, 1(3): 87-93.